ArticleCancers2022
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Novel Co-Occurrence of GermlineInternational journal of molecular sciences · 2026Article
- Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.International journal of molecular sciences · 2026Review
- Article
- Feasibility of Early DynamicMolecular imaging and biology · 2025Article
- Predictive and prognostic value of genetic aberrations of EGFR-TKI treatment: a real-world analysis ofJournal of thoracic disease · 2025Article
- Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer.The oncologist · 2025Article
- Unraveling the mechanisms of tricetin in renal cell carcinoma treatment through network pharmacology and experimental validation.Medical oncology (Northwood, London, England) · 2025Article
- Prediction of EGFR-TP53 genes co-mutations in patients with lung adenocarcinoma (LUAD) byClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Potential biomarkers of primary resistance to first- and second-generation EGFR-TKIs in non-small-cell lung cancer: a real-world study.Therapeutic advances in medical oncology · 2025Article
- Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial.EClinicalMedicine · 2024Article
- Osimertinib in uncommonTranslational lung cancer research · 2024Article
- Genetic profile of Chinese patients with small bowel cancer categorized by anatomic location.BMC medical genomics · 2023Article
- New Actions on Actionable Mutations in Lung Cancers.Cancers · 2023Article
- Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer.Frontiers in oncology · 2023Article
- The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia.F1000Research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.